Latest Conference Articles

Frontline Osimertinib/Chemotherapy Combination Improves PFS in EGFR-Mutated NSCLC

Osimertinib in combination with platinum-based therapy and pemetrexed demonstrated a statistically significant and clinically meaningful improvement in progression-free survival vs osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer.

Interim Results Show Durable Response With Dato-DXd in Advanced NSCLC

The addition of datopotamab deruxtecan to durvalumab, with or without carboplatin, demonstrated favorable efficacy and safety in patients with advanced or metastatic non–small cell lung cancer, according to an interim analysis of the phase 1b TROPION-Lung04 trial.

Dr Harpole on Perioperative Durvalumab Plus Chemotherapy in EGFR-Mutated NSCLC

David Harpole, MD, discusses findings from an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer.

Dr Jänne on Osimertinib Plus Platinum-Based Chemotherapy in EGFR-Mutant NSCLC

Pasi A. Jänne, MD, PhD, discusses findings from the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer.

TNO155/JDQ433 Combo Elicits Responses, Is Tolerable in KRAS G12C+ Solid Tumors

The combination of the SHP2 inhibitor TNO155 and the KRAS G12C inhibitor JDQ433 showed antitumor activity in patients with KRAS G12C-mutated solid tumors, including non–small cell lung cancer, irrespective of prior treatment with a KRAS G12C inhibitor.

Dose Optimization Continues After Preliminary Efficacy, Safety Signals With BI 764532 in DLL3+ SCLC

Treatment with at least 90 μg/kg of the novel DLLC-targeting T-cell–engager BI 764532 was well tolerated and led to tumor shrinkage in patients with small cell lung cancer and neuroendocrine carcinoma.

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

Treatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TKI–naïve, locally advanced and metastatic ALK-positive non–small cell lung cancer, according to data from a prespecified interim analysis of the phase 3 INSPIRE trial.

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

Treatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable safety profile.

Furmonertinib Generates Activity and Tolerable Safety in EGFR Exon 20 Insertion+ NSCLC

The use of the oral, brain penetrant, furmonertinib, resulted in encouraging responses and a tolerable safety profile in patients with advanced non–small cell lung cancer harboring EGFR exon 20 insertion mutations, according to data from the phase 1b FAVOUR trial.

Sacituzumab Govitecan Plus Pembrolizumab Evokes Clinical Activity as Frontline Treatment for Metastatic NSCLC

Early antitumor activity has been observed in patients with metastatic non–small cell lung cancer treated with the combination of sacituzumab govitecan-hziy and pembrolizumab in the first-line setting.

Repotrectinib Induces Durable Responses in ROS1+ NSCLC Subsets

Treatment with repotrectinib in patients with ROS1-positive non–small cell lung cancer, specifically those who were tyrosine kinase inhibitor-naïve or -pretreated, continued to demonstrate durable clinical activity, as well as durable intracranial responses.

Patritumab Deruxtecan Elicits Durable Responses in EGFR-Mutated NSCLC

Patritumab deruxtecan displayed clinically meaningful and durable efficacy in patients with advanced EGFR-mutated non–small cell lung cancer who experienced progression following treatment with an EGFR-directed TKI and platinum-based chemotherapy.

Adagrasib Yields Durable Benefit for Patients With KRAS G12C–Mutant NSCLC

Adagrasib monotherapy provided durable efficacy for patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, according to 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial.

Frontline Benmelstobart Plus Anlotinib/Chemo Improves Survival Vs Placebo in ES-SCLC

The addition of benmelstobart to anlotinib and etoposide plus carboplatin significantly improved progression-free survival and overall survival over placebo plus etoposide plus carboplatin when used in the first-line treatment of patients with extensive-stage small cell lung cancer.

Dr Garcia-Manero on the Efficacy of Luspatercept in Transfusion-Dependent MDS

Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.

Quizartinib Improves OS Irrespective of Allo-HCT in CR1 and Pre-Allo MRD Status in FLT3-ITD+ AML

Quizartinib plus standard intensive induction and consolidation therapy resulted in improved overall survival compared with placebo in patients with newly diagnosed, FLT3-ITD–positive AML irrespective of allogeneic hematopoietic cell transplantation in first complete remission and pre-allo minimal residual disease status.

Dr Erba on the Role of Quizartinib in Newly Diagnosed FLT3-ITD+ AML

Harry Erba, MD, PhD, discusses the role of quizartinib for the treatment of newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.

Data Suggest Interim PET2 Scans Can be Omitted for Frontline Brentuximab Vedotin Regimens in Hodgkin Lymphoma

The incorporation of brentuximab vedotin (Adcetris) into the frontline treatment of patients with Hodgkin lymphoma correlates with superior efficacy, irrespective of PET2 results, suggesting loss of predictive value with the scan.

Subcutaneous Epcoritamab Elicits Durable Responses in Relapsed/Refractory LBCL

Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory large B-cell lymphoma, with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.

Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular Lymphoma

Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

Dr Kahl on the Potential for Frontline BTK Inhibitors in Mantle Cell Lymphoma

Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.

Fixed-Duration Data Foreshadow Earlier Use of Loncastuximab Tesirine in Relapsed/Refractory DLBCL

Loncastuximab tesirine-lpyl plus rituximab demonstrated promising antitumor activity and consistent safety signals in patients with relapsed/refractory diffuse large B-cell lymphoma.

Quizartinib Plus Induction Chemotherapy Provides Survival Benefit in FLT3 ITD–Mutated AML

The addition of quizartinib to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia.

Chari Highlights Nuances of Choosing Between CAR T-cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Without a plethora of randomized and historic data to compare treatments, selection and sequencing strategies for patients with relapsed/refractory multiple myeloma must balance a multitude of factors, including adverse effect profiles, disease resistance mechanisms, and more.

Improved Molecular Understanding of AP/BP MPN Better Informs Management Approaches

Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.

Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.

Ongoing Investigations of Nelabarine and Daratumumab May Improve Outcomes in T-ALL

Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients with T-cell acute lymphoblastic leukemia by bolstering the efficacy of these standard frontline therapies.

Survival Outcomes May Be Impacted By Socio-Racial Factors in Primary Myelofibrosis

A retrospective analysis of the Surveillance, Epidemiology, and End Results database emphasized the potential impact of specific socio-racial factors, such as race, sex, and age, on survival outcomes in patients with primary myelofibrosis.

Dr Lin on the Outcomes of MRD-Negative Patients With R/R Myeloma After Cilta-Cel

Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.

Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

No difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hematopoietic stem cell transplantation in elderly patients over the age of 60 with acute myeloid leukemia in first complete remission.